On April 26, 2022 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") reported that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") for $5.60 per share in cash (Press release, Halozyme, APR 26, 2022, View Source [SID1234612982]). The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the "Merger Agreement").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on May 23, 2022, unless extended in accordance with the terms of the Merger Agreement. The closing of the tender offer is subject to certain conditions, including the tender of shares representing at least a majority of the total number of Antares’ outstanding shares of common stock, the expiration or termination of the HSR waiting period, and other customary conditions. The transaction is expected to close in the first half of 2022, as previously announced.

Halozyme filed today with the U.S. Securities and Exchange Commission (the "SEC") a tender offer statement on Schedule TO, which includes the terms of the tender offer. Additionally, Antares filed a Schedule 14D-9 with the SEC containing the recommendation of its Board of Directors that Antares stockholders accept the tender offer and tender their shares. The Schedule TO, Schedule 14D-9, related letter of transmittal (together with any amendments or supplements thereto) and other tender offer documents can be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the tender offer, D.F. King & Co., Inc., as described in the tender offer documents.

On April 26, 2022 TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, reported that the company will be participating in several upcoming conferences (Press release, TC Biopharm, APR 26, 2022, View Source [SID1234612998]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TC BioPharm Co-founder and Executive Chariman, Michael Leek will participate in the Allogeneic Cell Therapies Summit, at the Hilton Boston Northshore between 9-11 May, 2022. Michael is scheduled to co-present the workshop on Supply Chain Management for Multicentered Clinical Trial Set-up (May 9) and chair sessions on Supply/Storage and Manufacturing (May 10 and 11 respectively).

He will also be speaking at the Advanced Therapies Conference at ExCel in London, May 24-25. The conference will explore the hottest topics in the advanced therapy medicinal products (ATMP) space alongside a faculty of industry leading speakers, whilst showcasing the latest technologies and advancements in the industry.

This June, Dr. Leek will be featured at the Next Generation CAR & T Cell Therapies 2022. The event takes place June 14-16, 2022 at the Mark Hopkins Hotel in San Francisco, California. Dr. Leek is scheduled to present and co-chair a workshop on on June 14th at 2:15 pm in a session entitled; TC Biopharm Case Study: Phase 3 Studies of Our Lead Product in Blood Cancers.

Additionally, Dr. Leek and Co-founder and Chief Operating Officer, Angela Scott will be speaking at the Onco Cell Therapy Summit. This seminar will be held June 29-30 at the Hynes Convention Center in Boston, Massachusetts. Michael Leek’s seminar is entitled: Using banked unmodified allogeneic gamma-delta T cells to treat cancer, while Angela Scott will speak to; Manufacture of GMP-grade frozen allogeneic cell therapies for phase 2/3 clinical studies’. The Onco Cell Therapy Summit (OCTS) is the only industry-led meeting covering the full range of autologous and allogeneic cell product advancements.

On April 26, 2022 IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) ("IntelGenx"), a leader in pharmaceutical films, reported that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 3, 2022 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre (Press release, IntelGenx, APR 26, 2022, View Source [SID1234613051]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be broadcast live and archived on the Company’s website at www.intelgenx.com under "Webcasts" in the Investors section.

On April 26, 2022 Targovax ASA reported that members of its executive management team are invited for oral presentations and a panel discussion at the 5th Neoantigen Summit Europe in Amsterdam 27-28 April (Press release, Targovax, APR 26, 2022, View Source [SID1234612948]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation: Uncovering the Benefits of Personalized Vaccines in a Clinical Setting
Presenter: Dr. Erik Digman Wiklund (CEO)
Date: 27 April 2022
Time: 10:00 CET

Presentation: Clinical Combination Strategies with Oncolytic Vaccines in Solid Tumors
Presenter: Dr. Victor Levitsky (CSO)
Date: 28 April 2022
Time: 15:30 CET

Panel Discussion: Evaluating Combination Therapies to Maximize Anti-Tumour Immune Activity
Participants from Targovax: Erik Digman Wiklund (CEO), Victor Levitsky (CSO)
Date: 28 April 2022
Time: 16:00 CET

On April 26, 2022 Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, reported that it will host an R&D Symposium to provide an update on the Company’s three clinical programs (Press release, Corvus Pharmaceuticals, APR 26, 2022, View Source [SID1234612966]). The event will be held on Tuesday, May 10, 2022, in New York City from 9:00 – 11:30 am Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D symposium will cover the Company’s pipeline programs: anti-CD73 (mupadolimab), adenosine 2A receptor antagonist (ciforadenant), and an update on ITK inhibitor (CPI-818) in T cell lymphomas. It will be hosted by Corvus President and CEO Richard A. Miller, M.D., and will include speakers from Corvus as well as leading researchers:

Neel K. Gupta, M.D., Clinical Assistant Professor of Medicine at Stanford University School of Medicine – Division Oncology
Suresh Mahabhashyam, M.D., Vice President of Clinical Development at Corvus Pharmaceuticals
Erik Verner, Ph.D., Senior Vice President of Research at Angel Pharmaceuticals
The symposium will be webcast live from Corvus’s website at www.corvuspharma.com and the replay will be available for 90 days following the event.